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Background: Viruses exploit cell surface glycans to infect host cells.
Results: Different adeno-associated viral serotypes were engineered to display functional galactose receptor footprints.
Conclusion:Chimeric, galactose-bindingAAV strains display enhanced transduction efficiencywhilemaintaining endogenous
tissue tropism.
Significance: Grafting orthogonal glycan binding footprints onto AAV capsids can yield new chimeric strains with improved
transduction profiles for therapeutic gene transfer applications.
New viral strains can be evolved to recognize different host
glycans through mutagenesis and experimental adaptation.
However, such mutants generally harbor amino acid changes
that affect viral binding to a single class of carbohydrate recep-
tors. We describe the rational design and synthesis of novel,
chimeric adeno-associated virus (AAV) strains that exploit an
orthogonal glycan receptor for transduction. A dual glycan-
binding AAV strain was first engineered as proof of concept by
grafting a galactose (Gal)-binding footprint from AAV serotype
9 onto the heparan sulfate-binding AAV serotype 2. The result-
ing chimera, AAV2G9, continues to bind heparin affinity col-
umns but interchangeably exploits Gal and heparan sulfate
receptors for infection, as evidenced by competitive inhibition
assays with lectins, glycans, and parental AAV strains. Although
remaining hepatotropic likeAAV2, theAAV2G9 chimeramedi-
ates rapid onset and higher transgene expression in mice. Simi-
larly, engraftment of the Gal footprint onto the laboratory-de-
rived strain AAV2i8 yielded an enhanced AAV2i8G9 chimera.
This new strain remains liver-detargeted like AAV2i8 while
selectively transducingmuscle tissues at high efficiency, compa-
rable with AAV9. The AAV2i8G9 chimera is a promising vector
candidate for targeted gene therapy of cardiac and musculo-
skeletal diseases. In addition todemonstrating themodularity of
glycan receptor footprints on viral capsids, our approach pro-
vides design strategies to expand the AAV vector toolkit.
Virus-glycan interactions are critical determinants of host
cell invasion. Cell surface carbohydrates such as sialic acids,
gangliosides, or heparan sulfate are exploited by a vast number
of viruses such as influenza, herpesvirus, SV40, polyomavirus,
papillomavirus, and other pathogens (1, 2). In most cases, a
single class of glycans primarily serves as the cell surface attach-
ment factor for viruses, leading to sequential or parallel engage-
ment of other receptors/coreceptors for cell entry. Adeno-as-
sociated viruses (AAVs)2 are helper-dependent parvoviruses
that exploit heparan sulfate (HS), galactose (Gal), or sialic acids
(Sia) as primary receptors for cell surface binding (3, 4). For
instance, AAV serotypes 2 and 3b utilize HS. AAV1, 4, and 5
bind Sia with different linkage specificities, whereas AAV9
exploitsGal for host cell attachment.DifferentAAVstrains also
require subsequent interaction with coreceptors such as integ-
rin V5 or 51, fibroblast growth factor receptor, platelet-
derived growth factor receptor, EGF receptor, hepatocyte
growth factor receptor, or the laminin receptor for cellular
uptake (3, 4).
A notable exception to the monogamous relationship
between a specific AAV strain and a single class of carbohy-
drates is AAV serotype 6, which recognizes both Sia andHS (5).
However, only Sia has been shown to be essential for viral trans-
duction. Structural studies have now established that the Lys-
531 residue, in conjunctionwithArg-488, Lys-528, and Lys-533
in the VP3 subunit of the AAV6 capsid, forms a continuous
basic patch for electrostatic recognition of HS glycosaminogly-
cans (6–8). Similarly, the structural basis for HS recognition by
AAV2 and AAV3b is well known and attributed to similar clus-
ters of basic amino acid residues located at the 3-fold axis of
symmetry (9–12). The Sia binding footprints for AAV1, AAV4,
AAV5, and AAV6 remain to be determined.More recently, key
amino acid residues involved in Gal recognition by AAV9 cap-
sids were identified by using a combination of molecular mod-
eling and site-directed mutagenesis (13).
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In this study, we exploited the abundance of structural infor-
mation and knowledge pertaining to host receptor use by AAV
serotypes to design a new class of chimeric glycan-bindingAAV
vectors for gene transfer applications. A new dual glycan-bind-
ing strain (AAV2G9) and a chimeric, muscle-tropic strain
(AAV2i8G9) were generated by incorporating the Gal binding
footprint from AAV9 into the AAV2 VP3 backbone or the chi-
meric AAV2i8 capsid template using structural alignment and
site-directed mutagenesis. In vitro binding and transduction
assays confirmed the exploitation of both HS andGal receptors
by AAV2G9 for cell entry. Subsequent in vivo characterization
of the kinetics of transgene expression and vector genome bio-
distribution profiles indicate fast, sustained, and enhanced
transgene expression by this rationally engineered chimeric
AAV strain. A similar, improved transduction profile was
observed with the liver-detargeted, muscle-specific AAV2i8G9
chimera. These new reagents provide a framework for exploit-
ing the modularity of glycan receptor footprints to generate
improved AAV vectors for gene transfer.
EXPERIMENTAL PROCEDURES
Structural Modeling—Coordinates for the AAV2 and AAV9
viral protein (VP) crystal structures were obtained from the
RCSB Protein Data Bank (PDB codes 1LP3 and 3UX1, respec-
tively) (14, 15). Using the SWISS-MODEL protein structure
modeling server (16), homology models of the 2G9 and 2i8G9
VP3monomerswere generatedwith crystal structures ofAAV2
VP3 as template. Three-dimensional icosahedral models of
intact 2G9 and 2i8G9 capsids were created using the Oligomer
Generator utility in VIPERdb-Virus Particle ExploreR2 (17).
Similarly, illustration of the AAV2 VP3 trimer, 2i9 trimer, 2G9
trimer, 2i8G9 trimer, andAAV9 trimerwere obtained using the
Oligomer Generator utility. All structural models were visual-
ized using PyMOL, with residues forming the galactose binding
site (AAV9 VP1 numbering Asp-271, Asn-272, Tyr-446, Asn-
470, Ala-472, Val-473, and Trp-503) (13) and heparan sulfate
binding site (AAV2VP1 numberingArg-487, Lys-527, Lys-532,
Arg-585, and Arg-588) (10–12, 18) highlighted in orange and
purple, respectively. The i8 motif (AAV8 VP1 numbering 588-
QQNTAP-593) was colored in deep blue (19). In VP3 trimer
models, different monomers were colored in pale green, light
blue, and light pink.
Generation of Dual Glycan-binding AAV Strains—The
pXR2G9 chimera plasmid construct was generated by substi-
tuting amino acid residues directly involved and immediately
flanking the Gal recognition site on the AAV9 VP3 capsid pro-
tein subunit onto corresponding residues on the VP3 subunit
coding region of the helper plasmid pXR2 (AAV2VP3 number-
ing Q464V, A467P, D469N, I470M, R471A, D472V, S474G,
Y500F, and S501A). Substitutions were generated using the
QuikChange Lightning site-directed mutagenesis kit (Agilent)





ACCT-3. pXR2i8G9 was generated using the same set of
primers to introduce amino acid substitutions at the same res-
idues on the helper plasmid pXR2i8. RecombinantAAVvectors
packaging the CBA-Luc transgene cassettes were generated as
described previously, with modifications (20). Briefly, three
plasmids were transfected into HEK293 cells: the AAV helper
plasmid (pXR2, pXR2i8, pXR9, pXR2G9, or pXR2i8G9) encod-
ing the Rep2 and Cap genes, pXX6-80 containing the Adenovi-
ral helper genes, and the pTR-CBA-Luc plasmid with the
chicken -actin (CBA) promoter-driven firefly luciferase (Luc)
transgene flanked by inverted terminal repeats from the AAV2
genome. At 48–60 h post-transfection, cell pellets were col-
lected, and pooled supernatants were subjected to PEG precip-
itation (8% w/v PEG8000, 0.5 M NaCl final concentration). Cell
pellets and PEG precipitate were then pooled together prior to
sonication and CsCl ultracentrifugation. Peak fractions con-
taining the full viral particles were collected on the basis of
refractive indices and infectivity of each fraction in HEK293
cells. After dialysis with 1 PBS overnight, viral titers were
obtained by quantitative PCR using primers recognizing the
luciferase transgene (5-AAAAGCACTCTGATTGACAAA
TAC-3 (forward) and 5-CCT TCG CTT CAA AAA ATG
GAA C-3 (reverse)).
Heparin Affinity Chromatography—AAV2-CBA-Luc, AAV9-
CBA-Luc, 2G9-CBA-Luc, 2i8-CBA-Luc, and 2i8G9-CBA-Luc
were subjected to a heparin affinity column to assess their hep-
arin-binding characteristics. 1e11 vg of AAVparticles in 1ml of
1 PBS buffer was loaded onto pre-equilibrated heparin affin-
ity columns. After binding at room temperature for 30 min,
viruses on the heparin column were eluted using 150 mM Tris
buffer (pH 7.4) with an incrementally increasing concentration
of NaCl (150 mM, 200 mM, 250 mM, 300 mM, 350 mM, 400 mM,
450 mM, 500 mM, 550 mM, 600 mM, 650 mM, 700 mM, and 750
mM). 1 ml of each individual eluate was collected and subjected
to qPCR to quantify the total number of viral particles in each
fraction. The percentage of loaded virions was calculated as the
number of viral particles in eluate normalized by the total num-
ber of viral particles loaded onto the column.
In Vitro Binding and Transduction Assays—CHO-Pro5 and
CHO-Lec2 cells were cultured in  minimum Eagle’s medium
(Thermo Scientific) supplemented with 10% FBS, 100 units/ml
of penicillin (Cellgro), 100g/ml of streptomycin (Cellgro), and
2.5 g/ml of amphotericin B (Sigma). Cells were seeded at a
density of 1  105 cells/well in 24-well plates.
For competitive inhibition assays, CHO-Lec2 cells were
prechilled at 4 °C for 30 min and incubated with 100 g/ml of
FITC-labeled Erythrina crista-galli lectin (FITC-ECL, Vector
Laboratories) in  minimum Eagle’s medium at 4 °C for 1 h.
Alternatively, different viral capsids were incubated with 100
g/ml of soluble heparin (Sigma) or 1 PBS (control) at room
temperature for 1 h. Mock-treated or FITC-ECL-treated cells
were then infected with HS-bound or mock-treated AAV2,
AAV2G9, or AAV9 capsids packaging a CBA-Luc transgene
cassette at anMOI of 1000 vg copies/cell. Following incubation
in the cold room for 1 h, unbound virions were removed by
three washes with ice-cold 1 PBS. For cell surface binding
assays, the number of bound virions was measured by quanti-
fying vector genome copy numbers/cell in each well using
quantitative PCR. For transduction assays, infected Lec2 cells
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were moved to 37 °C and incubated for 24 h prior to quantita-
tion of luciferase transgene expression from cell lysates.
Competitive Inhibition Assays with Parental AAV Strains—
Parental AAV2, AAV9, or 2i8 vectors packaging a CBA pro-
moter-driven tdTomato transgene cassette were utilized as
competitors for transduction. Briefly, Lec2 cells were seeded in
24-well plates overnight at a density of 1  105 cells/well. After
being prechilled at 4 °C for 30 min, Lec2 cells were preincu-
bated with either AAV2-tdTomato, 2i8-tdTomato, or AAV9-
tdTomato vectors at multiplicities of infection ranging from
500–100,000 vg/cell at 4 °C for another 30min. Cells were then
superinfected with AAV2G9-CBA-Luc or AAV2i8G9-CBA-
Luc at an MOI of 1000 vg/cell for 45 min at 4 °C, followed by
removal of unbound virions using ice-cold PBS. Infected cells
were then incubated at 37 °C for 24 h prior to luciferase expres-
sion analysis. The luciferase activity shown in relative light
units indicates the transduction efficiency of the AAV2G9-
CBA-Luc or AAV2i8G9-CBA-Luc vectors.
In Vitro Transduction Assays—To compare the in vitro
transduction efficiency of Gal-binding chimeric strains with
the parental strains, AAV2i8, AAV2i8G9, andAAV9 packaging
the CBA-Luciferase transgenewere added to prechilled Pro5 or
Lec2 cell cultures at anMOI of 1000 vg/cell. After incubation at
4 °C for 1 h, unbound virions were removed by three washes
with ice-cold 1 PBS, and freshmediumwas added to the Pro5
and Lec2 cultures. 18–24 h post-transduction, cells were lysed
to quantify the expression efficiency of the luciferase transgene.
Kinetics of Transgene Expression in Vivo—Female BALB/c
mice (6–8 weeks old) were purchased from Jackson Laborato-
ries and handled in accordance with National Institutes of
Health guidelines using Institutional Animal Care and Use
Committee-approved protocols at theUniversity of NorthCar-
olina Chapel Hill. Different AAV vectors packaging the CBA-
Luc cassette were injected intravenously into the tail vein at a
dose of 1 1011 vg/mouse. At the indicated time intervals post-
administration (3, 7, and 18 days), mice were injected intraperi-
toneally with luciferin (120mg/kg, Nanolight), and biolumines-
cent images were obtained using a Xenogen IVIS Lumina
system (Caliper Lifesciences). Quantitation of light output
from liver and whole animal images was carried out using Igor-
Pro software (Wavemetrics). Further quantitation of lucifer-
ase transgene expression and vector genome biodistribution in
different tissues was carried out in two different groups of mice
that were sacrificed at days 3 and 18 post-vector administra-
tion. Luciferase transgene expression was monitored in differ-
ent tissue lysates as described earlier. Vector genome biodistri-
bution was determined by first extracting genomic DNA from
tissue lysates using a DNeasy kit (Qiagen). The luciferase
transgene copy number was determined using qPCR and nor-
malized toDNA concentration. Primers 5-AAAAGCACTCT-
GATTGACAAATA C-3 and 5-CCTTCGCTTCAAAA-
AATG GAAC-3 were used to quantify CBA-Luciferase
transgene copy number by qPCR.
Statistical Analysis—All data are expressed as mean  S.E.,
and the number of replicates for each experiment is provided in
the corresponding figure legends. Statistical significance was
determined using unpaired one-tail Student’s t test, and p 
0.05 was considered statistically significant for different exper-
iments unless indicated otherwise.
RESULTS
Construction of a Novel, Dual Glycan-binding AAV Strain—
To explore the feasibility of “grafting” the Gal footprint of
AAV9 onto several AAV strains, we first compared the three-
dimensional structures of the VP3 subunit trimers of AAV
serotypes 1, 2, 6, and 8 in alignment with that of AAV9. Amino
acid residues on the template capsids that overlapped with cor-
responding AAV9 VP3 residues directly involved in binding or
immediately flanking the Gal receptor footprint were modified
by multiple rounds of site-directed mutagenesis. The chimeric
AAV strains generated were prepared as recombinant vectors
packaging a chicken -actin promoter-driven firefly luciferase
(CBA-Luc) reporter transgene cassette using protocols estab-
lished previously (20). Amino acid residues involved in Gal rec-
ognition and other flanking residues from AAV9 were remark-
ably well tolerated on different AAV serotype capsids because
the packaging efficiencies of these AAV chimeras are compara-
blewith parental strains.MultipleAAVchimeras on the basis of
AAV serotypes 1, 2, 6, and 8 and the previously engineered
AAV2i8 mutant (19) were obtained (at titers ranging from 5 
1011 to 5  1012 viral genome copies/ml, data not shown). We
first carried out a detailed characterization of the dual glycan-
binding AAV chimera, dubbed AAV2G9 (where “g” stands for
the Gal footprint and the numbers identify the recipient and
donor capsid serotypes, respectively).
Three-dimensional models of the engineered AAV2G9 (full
capsid in Fig. 1A and VP3 trimer in D) with the putative dual
FIGURE 1. Three-dimensional models of the dual glycan-binding AAV2G9
chimera and its parental strains AAV2 and AAV9. A, three-dimensional
structural model of an intact AAV2G9 capsid with existing HS and “grafted”
Gal binding residues shown in purple and orange, respectively. B–D, illustra-
tions of the three-dimensional surface models of VP3 trimers at the 3-fold
symmetry axes of AAV2 (B), AAV9 (C), and AAV2G9 (D) capsids. Œ indicate the
3-fold axes of symmetry. Residues involved in HS binding (AAV2 VP1 number-
ing Arg-487, Lys-527, Lys-532, Arg-585, and Arg-588) and Gal binding (AAV9
VP1 numbering Asp-271, Asn-272, Tyr-446, Asn-470, Ala-472, Val-473, and
Trp-503) are highlighted as in A.
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glycan receptor binding sites (HS andGal) highlighted in purple
and orange were generated by homology modeling using
SWISS MODEL (Basel, Switzerland). The molecular model of
AAV2G9 full capsids demonstrates the geometrical distribu-
tion and orthogonality of HS and Gal binding sites located
around the 3-fold symmetry axis on the icosahedral capsid.
Close-up views of HS and Gal receptor footprints from the
3-fold axes further support the observation that grafting
orthogonal Gal binding sites on the backbone of the AAV2
capsid can be tolerated with regard to capsid assembly. Three-
dimensional structures of the AAV2 VP3 subunit trimer with
side chains of positively charged residues involved in HS recog-
nition (highlighted in purple, Fig. 1B) as well as the side chains
of amino acid residues comprising the Gal recognition site on
the AAV9 VP3 subunit trimer (highlighted in orange, C) are
also shown. The key residues involved in HS binding by AAV2
(VP1 numbering Arg-487, Lys-527, Lys-532, Arg-585, and Arg-
588; boldface andunderlined) are distinct frompreviously iden-
tified Gal binding residues on AAV9 (VP1 numbering Asp-271,
Asn-272, Tyr-446, Asn-470, Ala-472, Val-473, and Trp-503;
black arrowheads). Both key amino acids as well as flanking
residues were mutated (AAV2 VP1 numbering Q464V, A467P,
D469N, I470M, R471A, D472V, S474G, Y500F, and S501A;
white font, highlighted in black) to graft the three-dimensional
Gal-binding footprint onto the AAV2 template.
The Engrafted Gal Footprint Is Functionally Orthogonal to
theHS Footprint on the AAV2Capsid—On theAAV2G9 capsid
surface, the HS and Gal footprints are composed of distinct
amino acids (Fig. 1). Engraftment of the Gal footprint did not
change the packaging capacity of AAV2G9 compared with the
parental AAV2, as indicated by similar titers of viral prepara-
tions, supporting the structural compatibility of the Gal foot-
print with AAV2 capsid architecture. To probe for the impact
of Gal footprints on the global conformation and functionality
of AAV2 capsids, heparin affinity column chromatography was
carried out with AAV2G9 and the two parental strains, AAV2
and AAV9 (Fig. 2). In the case of AAV2 (Fig. 1A), viral particles
were eluted from the heparin affinity column in peak fractions
at a concentration of 450 mM saline, consistent with previous
publications (6, 21). In contrast, the Gal-binding AAV9
was found primarily in flow-through fractions at concentra-
tions as low as 150–200 mM, indicating a low affinity for HS
(Fig. 2C). The chimeric AAV2G9 demonstrates HS-binding
properties similar to that of AAV2 (Fig. 2B), with chimeric par-
ticles eluting at a concentration of 450mM saline. These results
suggest that the engraftment of aGal binding footprint onto the
AAV2 capsid does not alter the heparin-binding characteristics
of AAV2.
AAV2G9 Exploits HS and Gal Receptors Interchangeably in
Vitro—The first line of evidence supporting the usage of dual
glycan receptors by AAV2G9 was obtained from competitive
inhibition assays of virus binding on the cell surface involving
soluble heparin and ECL, which selectively binds terminally
galactosylated glycans. A mutant CHO cell line, CHO-Lec2, is
deficient in transporting CMP-sialic acids fromGolgi compart-
ments to the cell surface (22). Therefore, the majority of termi-
nal glycan moieties on the CHO-Lec2 surface are galactose.
This unique galactosylation pattern on the surface of CHO-
Lec2 and sialylation of wild-type CHO-Pro5 cells can be useful
in studying AAV-galactose/AAV-sialic acid interactions (23,
24). As seen in Fig. 3, A and C, HS, but not ECL, significantly
inhibits AAV2 transduction in CHO-Lec2 cells (dark gray
bars), whereas ECL selectively blocks AAV9 transduction by
nearly two log units (white bars). These results are consistent
with the expected transduction profiles for AAV2 and AAV9
(24–26). In contrast, AAV2G9 can only be effectively neutral-
ized by pretreatment with a combination of both ECL and HS
(light gray bars, Fig. 3B). A small but significant inhibitory effect
is observed for ECL.
The transduction profiles for AAV2, AAV9, and AAV2G9
were further corroborated by inhibition of cell surface binding
of each strain using ECL or HS (Fig. 3, D–F). The unique cell
surface attachment of the chimeric AAV strain is further sup-
ported by competitive inhibition of cell surface attachment of
AAV2G9 exclusively by a combination of ECL and HS but nei-
ther reagent alone (Fig. 3E). Such a scenario can be expected on
the basis of the apparent ability of AAV2G9 to bind two differ-
ent glycans interchangeably.
AAV2G9 Mediates Rapid Onset of Transgene Expression in
Vivo—We then investigated whether the orthogonal Gal foot-
print confers specific advantages to AAV2G9 transduction in
vivo. Live animal imaging studies were carried out to monitor
luciferase transgene expression following systemic administra-
tion of different AAV strains in BALB/c mice. Bioluminescent
FIGURE 2. Heparin binding characteristics of AAV2, AAV2G9, and AAV9. A, heparin affinity column chromatogram of parental AAV2 vectors. A total of 1e11
vg containing particles of AAV2-CBA-Luc in 1 ml of 1 PBS was loaded onto a heparin affinity column. Bound virions were eluted from the heparin affinity
column by elution with increasing NaCl concentration (right y axes, gray lines). The numbers of vg in the loaded sample and each eluted fraction were quantified
using qPCR as described under “Experimental Procedures.” The numbers of vg in each fraction were normalized to the total loaded vg to obtain the percentage
of recovered virions (left y axes, black lines). Heparin affinity column chromatograms of AAV2G9 (B) and AAV9 (C) were obtained through a similar approach.
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images (Fig. 4A) and quantitative assessment of light output
within the liver (B) and the whole animal (C) obtained at days 3,
7, and 18 post-injection support the notion that AAV2G9 can
mediate rapid onset and enhanced gene expression. As shown
in Fig. 4A, the kinetic profile displayed byAAV2G9mirrors that
of AAV9 but not AAV2. Further, the transduction profile/tis-
sue tropism of AAV2G9 appears to be primarily hepatotropic,
similar to AAV2 and, unlike the systemic tropism displayed by
AAV9, as established previously (4, 27–29). Quantitation of the
kinetics of bioluminescent signal output (Figs. 4, B and C) sug-
gests that the transduction efficiency of AAV2G9 is enhanced
in multiple organs. Notably, the efficiency and onset of liver
transduction by AAV2G9 is comparable with that of AAV9, as
quantified from live-animal images (Fig. 4B). Thus, dual glycan
receptor engagement appears to improve the transduction effi-
ciency and expedite the onset of transgene expression by this
chimeric AAV strain without altering tissue tropism.
To further evaluate the in vivo transduction profile of
AAV2G9, a quantitative analysis of tissue lysates from BALB/c
mice were carried out at 18 days post-administration. Specifi-
cally, the transduction efficiency of AAV2G9 in the brain, lung,
and spleen remains similar to that of AAV2 at 18 days post-
intravenous administration. Interestingly, AAV2G9 displays a
significantly higher luciferase transgene expression in the heart
(25-fold increase), liver (4-fold increase), skeletal muscle
(4-fold increase), and kidney (4-fold increase) compared
with the AAV2-treated group. Importantly, the transduction
efficiency of AAV2G9 in the liver is comparable with AAV9
(less than a 5-fold difference). These results support a potential
role for the orthogonal Gal receptor that might involve the cre-
ation of an alternative tissue uptake pathway(s). The latter
attribute could account for the uniform, multiorgan improve-
ment in the transduction profile of AAV2G9.
Construction of AAV2i8G9, an Artificial Gal-binding AAV
Strain—To further scrutinize the modularity and functionality
of the Gal binding footprint, the HS binding capacity of
AAV2G9 was abrogated by mutating the partial HS binding
linear motif (585-RGNRQA-590) to the corresponding motif
from AAV8 (585-QQNTAP-590). The resulting chimera,
AAV2i8G9, was thus constructed on the basis of an AAV2i8
chimera (19), thereby enabling studies solely focused on theGal
motif in the AAV2 capsid context. The original AAV2i8 chi-
mera has been described by our laboratory earlier (19). As
shown in Fig. 5, A and B, there is no overlapping amino acid
between the “I” motif from AAV8 (deep blue, AAV2i8G9 VP1
numbering 585-QQNTAP-590) and the “G” motif from AAV9
(orange; AAV2i8G9 VP1 numbering V464, P467, N469, M470,
A471, V472, G474, F500, and A501). The yield of AAV2i8G9
viral particles is similar to that of the parental strains of AAV2
and AAV9. This observation supports the notion that the latter
motifs are compatible with each other on an AAV2 capsid tem-
plate. Consistent with earlier studies (19), AAV2i8 is unable to
bind to HS, as shown by heparin affinity column chromatogra-
phy (Fig. 5C). Incorporation of a Gal footprint does not appear
FIGURE 3. In vitro characterization of the dual glycan-binding AAV2G9 chimera. A–C, inhibition of AAV2 (A), AAV2G9 (B), and AAV9 (C) transduction on CHO
Lec2 cells with FITC-ECL and soluble heparin. CHO Lec2 cells were prechilled at 4 °C and incubated with FITC-ECL, soluble heparin, or both prior to infection with
AAV2, AAV2G9, or AAV9 packaging a CBA-luciferase reporter transgene cassette. Transduction efficiency was measured 24 h post-infection as luciferase
activity in relative light units. The percentage of transgene expression was calculated by normalizing transduction efficiency to relative light units from
controls. Results are presented as mean  S.E. (n  4). D–F, inhibition of cell surface binding of AAV2 (D), AAV2G9 (E), and AAV9 (F) on CHO Lec2 cells with
FITC-ECL and soluble heparin. Different AAV particles were bound to cells prechilled at 4 °C, and unbound virions were removed by washing with cold PBS.
Bound virions were quantified using qPCR after viral genome extraction. The percentage of bound virions was determined by normalizing number of bound
virions to that of corresponding controls. Results are presented as mean  S.E. (n  5). Statistical significance was analyzed using one-tailed Student’s t test. *,
p  0.05; **, p  0.01.
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to affect the inability of the AAV2i8G9 to bind to the heparin
affinity column (Fig. 5D). Both chimeric strains were essentially
obtained in eluate fractions.
To further interrogate the exploitation of alternate transduc-
tion pathways by introducing the Gal motif, we conducted
competition assays of AAV2G9 and AAV2i8G9 with their cor-
responding parental serotypes. As shown in Fig. 6A, preincuba-
tion with competing vectors AAV2-CBA-tdTom (solid line, ●)
or AAV9-CBA-tdTom (dotted line, Œ) at MOIs ranging from
500 to 100,000 vg/cell does not efficiently block transduction in
CHO-Lec2 cells by AAV2G9-CBA-Luc, as measured by lucif-
erase transgene expression at 24 h post-transduction. Only
mild inhibitory effects were visible at 10-fold MOI of AAV2-
tdTom (10%) or AAV9-tdTom (10%). At higherMOI (100-
fold excess), AAV2 appears to compete less effectively (30%
inhibition) than AAV9 (60% inhibition) by neutralizing
AAV2G9 transduction. Taken together, these results support
the notion that AAV2G9 is indeed a novel, dual glycan-binding
strain with the unique ability to exploit both HS and Gal inter-
changeably as primary receptors for transduction.
A similar competitive inhibition assay was carried out with
AAV2i8G9 (Fig. 6B). AtMOI of the competingAAV2i8-tdTom
ranging from 500–100,000 vg/cell, the transduction efficiency
of AAV2i8G9 on CHO-Lec2 cells was not affected significantly
compared with control Lec2 cells transduced with AAV2i8G9-
CBA-Luc vectors alone. This observation is consistent with the
inability of both AAV2i8 and AAV2i8G9 to bind HS on the cell
surface. In contrast, in the presence of competing AAV9-
tdTom, which binds Gal, transduction of Lec2 cells by
AAV2i8G9 is blocked efficiently.With an equalMOI of AAV9-
tdTom andAAV2i8G9-CBA-Luc present, only 48% of the Lec2
cells were transduced by AAV2i8G9 compared with the con-
trol.When therewas a 10-fold excess of AAV9-tdTomcompet-
itors present, the transduction efficiency of AAV2i8G9 was
blocked by 80%. At 100-fold excess, AAV9-tdTom 93%
inhibition of AAV2i8G9 transduction was observed. These
results support the notion that AAV2i8G9 utilizes Gal as the
primary glycan receptor for cell surface attachment and entry.
In Vitro and in Vivo Transduction Profiles of AAV2i8G9—
The in vitro characterization of AAV2i8G9 was carried out on
CHO-Pro5 and CHO-Lec2 cells with its parental controls,
AAV2i8 and AAV9 (Fig. 7B). In vitro transduction assays indi-
cate that AAV2i8G9 transduces CHO-Lec2 cells as efficiently
as AAV9, supporting the notion that Gal is a primary recep-
tor for this chimeric strain. The transduction efficiency of
AAV2i8G9 on CHO-Lec2 is 3 orders of magnitude higher
than that on CHO-Pro5 because of the abundance of terminal
galactose on the CHO-Lec2 cell surface. Similar trends have
been reported for AAV9, which binds to galactose on theCHO-
Lec2 cell surface (24, 26). A modest increase in transduction
efficiency of AAV2i8G9 compared with AAV2i8 on CHO-Pro5
was noted, most likely because of interactions with residual
terminal galactose residues on CHO-Pro5.
The in vivo transduction profiles of AAV2i8G9 were ob-
tained at days 3, 7, and 18 post-intravenous administration in
BALB/c mice (Fig. 7A). As reported earlier by our group,
FIGURE 4. AAV2G9 mediates rapid onset and enhanced transgene expression in vivo. A, in vivo transgene expression kinetics of AAV2, AAV2G9, and AAV9
vectors packaging a CBA-luciferase transgene cassette. BALB/c mice (n  4) were administered AAV vectors at a dose of 1  1011 vg/animal through the tail
vein, and bioluminescent images were collected at 3, 7, and 18 days post-injection using an Xenogen Lumina imaging system. Representative live animal
images are shown with bioluminescence on a rainbow-colored scale (1  105-1  106 photons/second/cm2/steradian). AAV2G9 maintains the hepatic tropism
of AAV2 but demonstrates a more rapid and robust luciferase signal than both parental AAV strains. B and C, quantitation of the kinetics of light signal output
(expressed as photons/second/cm2/steradian) was performed by marking regions of interest around images of the liver regions (B) and entire animals (C)
obtained at different time intervals (n  4). RLU, relative light unit. D, quantitation of luciferase transgene expression in major tissues from AAV2- (black),
AAV2G9- (gray), or AAV9-treated (white) animals at 18 days post-administration (n  4). BALB/c mice (n  4) were administered AAV2, AAV2G9, or AAV9
packaging a CBA-Luciferase cassette at a dose of 1  1011 vg/animal through the tail vein. At 18 days post-vector administration, animals were sacrificed to
harvest brain, heart, liver, lung, spleen, skeletal muscle, and kidney tissues. Luciferase transgene expression in these tissue lysates was measured using a
luminometer and normalized by the total amount of protein in each sample, determined using a Bradford assay. Statistical significance was assessed using
one-tailed Student’s t test. *, p  0.05; **, p  0.01.
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AAV2i8 is detargeted from the liver and demonstrates selective
tropism for cardiac and skeletal muscle (19). As shown in live
animal images, AAV2i8G9 retains a liver-detargeted transduc-
tion profile similar to that of AAV2i8. Notably, the kinetics of
transgene expressionmediated by AAV2i8G9 in the entire ani-
mal are comparable with those of AAV9 and more rapid than
AAV2i8 (Fig. 7C). Luciferase expression levels in tissue lysates
from BALB/c mice at 18 days post-administration further cor-
roborate these observations (Fig. 7D). In murine heart, liver,
lung, and kidney tissues, AAV2i8G9 shows a transduction effi-
ciency in between that of AAV2i8 and AAV9. Importantly, trans-
gene expression mediated by AAV2i8G9 in the liver is only
5-fold higher than that of AAV2i8 but remains nearly 200-fold
less than that of AAV9. In addition, AAV2i8G9 demonstrates a
modestly higher efficiencywhen comparedwith eitherAAV2i8 or
AAV9 in skeletalmuscle. Taken together, these observations con-
FIGURE 5. Structural attributes of the AAV2i8G9 chimera. A, three-dimensional illustration of the intact AAV2i8G9 capsid. The surface-exposed motif derived
from AAV8 (AAV8 VP1 numbering 588-QQNTAP-593) and the Gal binding site from AAV9 (AAV9 VP1 numbering Asp-271, Asn-272, Tyr-446, Asn-470, Ala-472,
Val-473, and Trp-503) are shown in deep blue and orange, respectively. B, close-up view of the 3-fold axes of symmetry (Œ) on the exterior of the AAV2i8G9
capsid. Three individual VP3 monomers are shown in pale green, light blue, and pale pink. The structural motifs derived from the AAV8 and AAV9 motifs are
highlighted as described in A. C and D, heparin affinity column chromatograms of the parental AAV2i8 strain (C) and the AAV2i8G9 chimera (D). A total of 1e11
vg of AAV2i8 or AAV2i8G9 vectors in 1 ml of 1 PBS were loaded onto heparin affinity columns. Virions were eluted from the column with elution buffers
containing increasing concentrations of NaCl (right y axes, gray lines). The percentage of recovered virions in each elution fraction (left y axes, black lines) was
obtained by normalizing the total number of vg in each fraction to that in the loaded sample.
FIGURE 6. Competitive inhibition of AAV2G9 and AAV2i8G9 by parental AAV serotypes. A, CHO Lec2 cells were preincubated with AAV2 or AAV9-CBA-
tdTomato at MOI ranging from 500 –100,000 vg/cell for 2 h. Pretreated cells were then infected with AAV2G9-CBA-Luc particles (MOI  1000 vg/cell). At 24 h
post-transduction, cells were lysed to assess luciferase activity. Percentage inhibition of AAV2G9 transduction was calculated by normalizing luciferase
transgene expression levels to that of control with no AAV competitors. B, competitive inhibition of AAV2i8G9-CBA-Luc transduction by AAV2i8-tdTomato and
AAV9-tdTomato was carried out in a similar fashion. The percentage of luciferase expression was obtained by normalizing the luciferase transgene expression
in each condition by that of the control condition without any competitor AAV. Results are presented as mean  S.E. (n  4). Statistical significance was
analyzed using one-tailed Student’s t test. *, p  0.05; **, p  0.01.
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firm that engraftment of a Gal binding footprint onto AAV2/
AAV2i8 capsid templates increases transduction efficiency with-
out altering the endogenous tissue tropism of these strains.
DISCUSSION
This study demonstrates that grafting conformational recep-
tor footprints from one AAV strain onto another template is
feasible. This strategy can clearly yield new chimeric AAV cap-
sids with enhanced transduction profiles in vitro and in vivo.
The overall approach was made possible by earlier reports that
utilized molecular docking and alanine scanning mutagenesis
to dissect structure-function correlates of AAV9-galactose
interactions (13, 30). The dual glycan-binding chimera
AAV2G9 was synthesized by incorporating residues from
within or around the Gal binding pocket on AAV9 onto the
AAV2 capsids. In addition, the Gal-binding AAV2i8G9 was
constructed by deleting the partial HS footprint fromAAV2G9.
Remarkably, a minor change of nine residues in the primary
amino acid sequence of the AAV2 VP3 subunit (1.4%) was
sufficient to impartGal recognizing abilitywithout affectingHS
binding.
These results are particularly unique from a structural per-
spective. For instance, in the case of influenza A, mutations
within a single sialic acid binding site have been associated with
altered recognition of glycan linkage specificities by new reas-
sortant strains (31, 32). However, it is noteworthy that the Gal-
and HS-binding residues on AAV2G9 create two distinct and
independent footprints on the viral capsid surface. Further,
AAV2G9 appears to utilize HS and Gal simultaneously and
interchangeably. On the other hand, the HS binding-deficient
AAV2i8G9 strain is capable of engaging Gal alone to initiate
transduction. Overall, this study sheds light on the modularity
of the cluster of residues that form the “G9”motif on theAAV9
capsid. On the basis of a similar rationale, our studies might
provide design parameters for synthesizing a panel of orthogo-
nal, dual, or perhaps even multiglycan receptor-binding AAV
strains that might display enhanced transduction profiles.
Our results also provide insights into the biology of AAV
receptor use in vivo. First, the tissue tropism of AAV2G9 and
2i8G9 in vivo appears to be dictated by one of the parental AAV
serotypes, which composes a majority of the capsid structure.
Specifically, AAV2G9 remains predominantly liver-tropic, like
AAV2, whereas AAV2i8G9 is liver-detargeted, like the labora-
tory-derived AAV2i8 strain described earlier (15). This implies
that utilization of the Gal receptor by AAV2G9/AAV2i8G9 is
compatible with coreceptors such as fibroblast growth factor
receptor, hepatocyte growth factor receptor, and/or integrins
known to play a role in AAV2 cell entry (3, 4). Further, because
Gal binding does not alter tissue tropism, it is tempting to spec-
ulate that the HS binding property of AAV2 is the primary
determinant of liver tropism for this serotype. One question
that follows this observation is whether incorporation of other
glycan-binding footprints onto AAV2 or other serotypes (e.g.
FIGURE 7. AAV2i8G9 demonstrates an enhanced and selective transduction profile in skeletal muscle. A, in vivo transgene expression kinetics of AAV2i8,
AAV2i8G9, and AAV9 vectors packaging the CBA-luciferase transgene cassette. BALB/c mice (n  4) were administered AAV2i8, AAV2i8G9, and AAV9 vectors
at a dose of 1  1011 vg/animal through the tail vein. Live animal bioluminescent images were collected at 3, 7, and 18 days post-injection using an Xenogen
Lumina imaging system. Representative live animal images are shown on a rainbow-colored scale (1  105-1  106 photons/second/cm2/steradian). B, in vitro
transduction efficiency of AAV2i8, AAV2i8G9, and AAV9 on CHO-Pro5 and Lec2. Vectors packaging CBA-luciferase were bound to prechilled Pro5 or Lec2 at an
MOI of 1000 vg/cell at 4 °C for 1 h. Unbound virions were removed by three washes with ice-cold 1 PBS, and luciferase transgene expression was measured
at 18 –24 h post-infection. Results are shown in relative light units (RLU) (n  5). Statistical significance was analyzed using one-tailed Student’s t test. *, p  0.05;
**, p  0.01. C, quantitation of the kinetics of transgene expression by AAV2i8, AAV2i8G9, and AAV9 in BALB/c mice. Regions of interest were marked around
the entire animals in live-animal images (A) to measure the light signal output (expressed as photons/second/cm2/steradian) from the mice at different time
intervals (n  4). Statistical significance was assessed to compare AAV2i8 and AAV2i8G9 as well as AAV9 and AAV2i8G9. D, in vivo transduction efficiency of
AAV2i8, AAV2i8G9, and AAV9 in BALB/c mice. At 18 days post-administration, animals were sacrificed, and luciferase transgene expression in tissue lysates from
brain, heart, liver, lung, spleen, muscle, and kidney were determined using a luminometer. Results are normalized to the amount of protein in each sample
measured by Bradford Assay and presented as mean  S.E. (n  4). Statistical significance was assessed using one-tailed Student’s t test. n.s., not significant; *,
p  0.05.
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Sia) will yield viable chimeric strains. Consequently, whether
incorporation of other orthogonal glycan-binding footprints
will enhance transduction and/or alter tropism remains to be
seen. Nevertheless, such studies will likely shed more light on
the specific role(s) played by different cognate glycan receptors
in determining the tissue tropisms of different AAV serotypes.
We are currently examining the mechanism by which
orthogonal Gal binding footprints enhance transduction effi-
ciency in vitro and in vivo. Preliminary studies with galactose-
overexpressing CHO-Lec2 cells suggest that the dual glycan-
binding AAV2G9 strain binds more efficiently to the cell
surface. This observation can be attributed to increased binding
avidity to cell surface glycans. As a consequence, dual glycan-
binding strains might show increased cellular uptake. Another
aspect being explored is whether intracellular trafficking of
dual glycan-binding strains follows alternative pathways that
are consistent with HS or Gal receptor-mediated cell entry.
Another potential scenario is the exploitation of a novel intra-
cellular pathway(s) by chimeric strains that requires simultane-
ous engagement of HS and Gal moieties on the cell surface.
Regardless of the outcome, such mechanistic studies are likely
to help understand and possibly manipulate the interplay
between host glycans and AAV serotypes.
For the gene therapy community, the new technology
reported here provides a platform to develop improved clinical
reagents. The orthogonal Gal-binding footprint clearly initiates
earlier transgene expression that continues to increase at a
faster rate compared with the less efficient parental AAV sero-
type. Although the transduction efficiencies of either chimeric
strain did not surpass AAV9, the endogenous tissue tropisms of
AAV2G9 and AAV2i8G9 (i.e. liver and muscle, respectively)
remain unaltered. For instance, AAV2i8G9 is a one-of-a-
kind, chimeric strain that can potentially serve as a vector
candidate for selective gene transfer to cardiac and muscu-
loskeletal tissue through intravenous infusion. Specifically,
the selective muscle tropism and ability to avoid liver seques-
tration makes AAV2i8G9 an optimal vector for systemic gene
therapy of muscular dystrophies (33–35). We determined
recently that the strain described previously, AAV2i8, yields
sustained transgene expression levels in primatemuscle tissue3.
Similar validation of AAV2i8G9 vectors in large animal models
is forthcoming and will hopefully provide an attractive candi-
date for advancing toward the gene therapy clinic.
From a continued vector development standpoint, whether
our new vector-engineering approach can be integrated syner-
gistically with other major advancements in AAV technology
(e.g. self-complementary vectors (36) or Tyr-to-Phe capsid
mutations (37)) remains to be seen. The ultimate goal of such
efforts is to continue to improve AAV vector technology that
would help decrease the effective vector dose required for
achieving therapeutically relevant transgene expression levels.
These technological advancements are also likely to help alle-
viate potential clinical concerns associated with vector dose-
dependent toxicity (38, 39). In summary, rational engineering
of capsid-glycan receptor interactions is a promising approach
toward continued improvement of the preclinical/clinical pipe-
line of AAV vectors for gene therapy. Improved structural
understanding and manipulation of receptor-binding foot-
prints on different AAV isolates as well as other closely related
parvoviruses could help to further expand the AAV vector
toolkit.
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